Ligand ID: 1KX


Drugbank ID:
DB01048
(Abacavir)


Indication:
For the treatment of HIV-1 infection, in combination with other antiretroviral agents.

Get human targets for 1KX in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND '1KX'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		3 / 3
THR A  98
VAL A  18
VAL A  20
1.10A2.89
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		1x7q HLA, A-11
(Homo
sapiens)		6 / 12
TYR A   9
ILE A  95
TYR A  99
TYR A 123
ILE A 124
TRP A 147
0.23A88.00
9.84
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		1x7q HLA, A-11
(Homo
sapiens)		6 / 10
TYR A   9
ILE A  95
TYR A  99
TYR A 123
ILE A 124
TRP A 147
0.23A88.00
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		1x7q HLA, A-11
(Homo
sapiens)		5 / 10
TYR A   9
TYR A  99
TYR A 123
ILE A 124
TRP A 147
0.25A88.00
4.35
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		1x7q HLA, A-11
(Homo
sapiens)		6 / 10
TYR A   9
ILE A  95
TYR A  99
TYR A 123
ILE A 124
TRP A 147
0.26A88.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE B1200
LEU B1205
VAL B1261
0.91A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2a5i 3C-LIKE PEPTIDASE
(SARSr-CoV)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.95A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2ajf SPIKE PROTEIN
(SARSr-CoV)		3 / 3
ILE E 345
LEU E 499
VAL E 420
0.83A6.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
THR A  98
VAL A  18
VAL A  20
1.05A2.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE B 200
LEU B 205
VAL B 261
0.97A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE S 345
LEU S 499
VAL S 420
0.90A5.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2dd8 IGG LIGHT CHAIN
(Homo
sapiens)		3 / 3
THR L  22
VAL L  11
VAL L  13
1.17A7.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2fyg REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 4
ILE A  81
TYR A  76
LEU A  75
VAL A 108
1.47A7.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		4 / 4
ILE E  81
TYR E  76
LEU E  75
VAL E 108
1.28A5.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE A 345
LEU A 499
VAL A 420
0.91A9.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2gri NSP3
(SARSr)		3 / 3
THR A  49
VAL A  22
VAL A  42
0.57A23.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		2kqv NSP3
(SARSr-CoV)		5 / 10
ILE A  51
VAL A  52
TYR A  54
TYR A  61
ILE A  27
1.69A21.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2ofz NUCLEOCAPSID PROTEIN
(SARS-COV
Tor2)		3 / 3
THR A 166
VAL A 134
VAL A 132
1.16A6.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
THR C  83
VAL C  66
VAL C 162
0.99A5.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		3 / 3
ILE A 200
LEU A 205
VAL A 261
0.73A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
TYR D 237
ILE D 235
VAL D 236
ILE D 305
ILE D 306
1.61A21.72
5.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
THR E  83
VAL E  66
VAL E 162
1.08A5.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		2wct NSP3
(SARSr-CoV)		3 / 3
THR B 485
VAL B 457
VAL B 445
0.94A10.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2xyq NSP10
(SARSr-CoV)		4 / 4
ILE B  81
TYR B  76
LEU B  75
VAL B 108
1.45A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
TYR A 152
SER A 129
ILE A 128
THR A 120
ILE A 167
1.46A21.99
5.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 4
ILE A 219
TYR A 181
LEU A 206
VAL A 169
1.45A2.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
TYR A 152
SER A 129
ILE A 128
THR A 120
ILE A 167
1.45A21.34
5.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2xyv NSP10
(SARSr-CoV)		4 / 4
ILE B  81
TYR B  76
LEU B  75
VAL B 108
1.45A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 4
ILE A 219
TYR A 181
LEU A 206
VAL A 169
1.44A4.73
 CL  A1296 ( 4.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3avz 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.94A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		3 / 3
ILE A 345
LEU A 499
VAL A 420
1.00A3.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		3bgf F26G19 FAB
SPIKE PROTEIN S1
(Mus
musculus;
SARSr-CoV)		5 / 10
TYR S 491
VAL L  92
TYR L  32
SER L  93
ILE L   2
1.71A22.46
5.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		3bgf F26G19 FAB
SPIKE PROTEIN S1
(Mus
musculus;
SARSr-CoV)		5 / 10
TYR S 491
VAL L  92
TYR L  32
SER L  93
ILE L   2
1.72A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE E 345
LEU E 499
VAL E 420
0.83A6.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3d0h SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE F 345
LEU F 499
VAL F 420
0.97A6.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3d0i SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE F 345
LEU F 499
VAL F 420
0.98A6.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 4
ILE B 513
TYR B 516
LEU B 450
VAL B 447
1.63A2.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
TYR B 199
VAL B 184
TYR B 183
TRP B 459
ILE B 468
1.54A19.20
3.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
TYR B 199
VAL B 184
TYR B 183
TRP B 459
ILE B 468
1.56A19.20
25.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3d62 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.00A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3e9s NSP3
(SARSr-CoV)		3 / 3
ILE A 223
LEU A 186
VAL A 236
0.80A3.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3ea8 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.95A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3ea9 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.95A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE A 200
LEU A 205
VAL A 261
0.75A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.95A3.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.64A3.86
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 10
TYR D 118
TYR D 123
ILE D 124
ASP D  74
ILE F   7
1.70A87.96
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 10
TYR D 118
TYR D 123
ILE D 124
ASP D  74
ILE F   7
1.71A87.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		3i6l HLA, A-24
(Homo
sapiens)		3 / 3
THR D 216
VAL D 247
VAL D 249
1.24A3.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
THR B  98
VAL B  18
VAL B  20
1.03A2.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3r24 NSP10 AND NSP11
(SARSr-CoV)		4 / 4
ILE B  81
TYR B  76
LEU B  75
VAL B 108
1.53A4.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 4
ILE A 219
TYR A 181
LEU A 206
VAL A 169
1.41A3.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
TYR A 152
SER A 129
ILE A 128
THR A 120
ILE A 167
1.51A21.80
5.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		3sci ACE2
(Homo
sapiens)		3 / 3
THR B 334
VAL B 364
VAL B 298
1.13A4.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3scj SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE E 345
LEU E 499
VAL E 420
0.91A6.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
TYR B 199
VAL B 184
TYR B 183
TRP B 459
ILE B 468
1.57A19.20
25.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 4
ILE B 513
TYR B 516
LEU B 450
VAL B 447
1.63A2.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
TYR B 199
VAL B 184
TYR B 183
TRP B 459
ILE B 468
1.55A19.20
3.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		4mm3 UBIQUITIN
(Homo
sapiens)		3 / 3
ILE A  61
LEU A  43
VAL A  70
0.66A23.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		3 / 3
ILE B 223
LEU B 186
VAL B 236
0.92A2.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		4 / 4
ILE A 130
TYR A  72
LEU A  71
VAL A  13
1.10A4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		3 / 3
ILE A 130
LEU A  71
VAL A  13
0.99A4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		4tww 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
THR B  98
VAL B  18
VAL B  20
1.06A3.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5c8t NSP10
(SARSr-CoV)		4 / 4
ILE A  81
TYR A  76
LEU A  75
VAL A 108
1.31A6.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5e6j POLYUBIQUITIN-B
(synthetic
construct)		3 / 3
ILE F  61
LEU F  43
VAL F  70
0.90A23.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5e6j UBIQUITIN
(synthetic
construct)		3 / 3
ILE E  61
LEU E  43
VAL E  70
0.95A23.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 4
ILE O  81
TYR O  76
LEU O  75
VAL O 108
1.34A7.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5r82 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.94A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.75A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.34A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 208
VAL A 204
1.59A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  18
1.60A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.00A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ILE B 223
LEU B 186
VAL B 236
0.97A2.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
ILE C 724
TYR C 723
LEU C 986
VAL C 990
1.58A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE A 345
LEU A 499
VAL A 420
0.80A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
TYR A  88
VAL A  66
ILE A  81
THR A  92
ILE A  87
1.59A19.22
4.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		3 / 3
ILE C 345
LEU C 499
VAL C 420
0.79A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		5x59 S PROTEIN
(MERS-CoV)		3 / 3
THR A 693
VAL A 661
VAL A 360
1.00A1.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ILE A 702
VAL A1047
TYR A1049
ILE A 891
THR A 863
1.25A11.54
0.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
TYR A 646
TYR A 677
VAL A 675
ILE A 584
ILE A 652
1.64A11.54
0.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		3 / 3
THR B 517
VAL B 525
VAL B 308
1.14A1.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 4
ILE C 724
TYR C 723
LEU C 986
VAL C 990
1.61A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		5x5c S PROTEIN
(MERS-CoV)		5 / 10
TYR C 648
VAL C 631
ASP C 633
SER A  65
ILE A  67
1.78A11.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		5x5c S PROTEIN
(MERS-CoV)		5 / 10
TYR C 648
VAL C 631
ASP C 633
SER A  65
ILE A  67
1.78A12.16
1.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR B  88
ILE B  87
VAL B 254
ILE B 234
TRP B 101
1.67A11.87
TYR  B  88 ( 1.3A)
ILE  B  87 ( 0.6A)
VAL  B 254 ( 0.6A)
ILE  B 234 ( 0.7A)
TRP  B 101 ( 0.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR A 256
VAL A 254
TYR A 252
TRP A 101
ILE A 234
1.60A11.90
0.85
TYR  A 256 ( 1.3A)
VAL  A 254 ( 0.6A)
TYR  A 252 ( 1.3A)
TRP  A 101 ( 0.5A)
ILE  A 234 ( 0.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
THR C 624
VAL C 606
VAL C 307
1.18A1.15
THR  C 624 ( 0.8A)
VAL  C 606 ( 0.6A)
VAL  C 307 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 702
VAL C1047
TYR C1049
ILE C 891
THR C 863
1.49A11.90
0.87
ILE  C 702 ( 0.7A)
VAL  C1047 ( 0.6A)
TYR  C1049 ( 1.3A)
ILE  C 891 ( 0.7A)
THR  C 863 ( 0.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR B  88
ILE B  87
VAL B 254
ILE B 234
TRP B 101
1.68A11.87
TYR  B  88 ( 1.3A)
ILE  B  87 ( 0.6A)
VAL  B 254 ( 0.6A)
ILE  B 234 ( 0.7A)
TRP  B 101 ( 0.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		5y3q REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
ILE A 223
LEU A 186
VAL A 236
0.96A2.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR A 677
VAL A 675
TYR A 660
ILE A 584
ILE A 652
1.51A11.99
0.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE A 702
VAL A1047
TYR A1049
ILE A 891
THR A 863
1.29A11.99
0.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
THR A 160
VAL A 114
VAL A 102
1.06A1.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE A 345
LEU A 499
VAL A 420
0.59A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
ILE C 724
TYR C 723
LEU C 986
VAL C 990
1.50A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR A 646
TYR A 677
VAL A 675
TYR A 660
ILE A 584
1.61A11.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR A 646
TYR A 677
VAL A 675
TYR A 660
ILE A 584
1.59A11.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
THR A 160
VAL A 114
VAL A 102
1.08A1.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE C 702
VAL C1047
TYR C1049
ILE C 891
THR C 863
1.20A11.71
0.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
ILE B 345
LEU B 499
VAL B 420
0.88A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE A 702
VAL A1047
TYR A1049
ILE A 891
THR A 863
1.24A11.94
0.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 4
ILE B 724
TYR B 723
LEU B 986
VAL B 990
1.58A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
THR B 363
VAL B 496
VAL B 388
0.75A1.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
TYR B 438
TYR B 481
VAL B 388
ILE B 397
ILE B 405
1.68A11.94
0.85
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens;
SARSr-CoV)		5 / 12
TYR A  74
TYR A  99
TYR A 123
ILE A 124
THR C   3
0.45A89.05
23.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens;
SARSr-CoV)		3 / 3
ILE A  66
LEU C   5
VAL A 152
0.87A3.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6jyt HELICASE
(SARSr-CoV)		5 / 12
ILE B 572
VAL B 544
TYR B 541
ILE B 570
ILE B 448
1.59A18.38
2.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6jyt HELICASE
(SARSr-CoV)		3 / 3
ILE B 333
LEU B 363
VAL B 386
0.73A1.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6jyt HELICASE
(SARSr-CoV)		3 / 3
THR B 416
VAL B 558
VAL B 456
1.20A4.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.35A4.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.22A4.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.73A4.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.01A4.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ILE B 358
LEU B 513
VAL B 433
0.88A6.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m0j ACE2
(Homo
sapiens)		5 / 10
TYR A 199
VAL A 184
TYR A 183
TRP A 459
ILE A 468
1.59A19.20
3.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m0j ACE2
(Homo
sapiens)		4 / 4
ILE A 513
TYR A 516
LEU A 450
VAL A 447
1.63A1.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.34A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.73A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.02A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.21A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
TYR A 507
VAL A 506
ILE A  92
TRP A 104
ILE A 107
1.50A17.81
7.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		3 / 3
ILE E 358
LEU E 513
VAL E 433
0.99A6.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
TYR A 507
VAL A 506
ILE A  92
TRP A 104
ILE A 107
1.48A17.81
4.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m18 ACE2
(Homo
sapiens)		5 / 10
TYR D 199
VAL D 184
TYR D 183
TRP D 459
ILE D 468
1.58A15.82
3.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		3 / 3
ILE A 401
LEU A 398
VAL A  55
0.70A9.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m1d ACE2
(Homo
sapiens)		6 / 12
TYR D 207
ILE D 513
TYR D 521
TYR D 454
THR D 567
ILE D 223
1.44A15.82
4.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE B  43
LEU B  89
VAL B  35
1.21A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.32A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE B 259
LEU B 205
VAL B 204
1.30A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 4
ILE B 259
TYR B 209
LEU B 253
VAL B 297
1.75A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE B  78
LEU B  75
VAL B  73
1.03A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE C  43
LEU C  89
VAL C  35
1.17A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 4
ILE D 259
TYR D 209
LEU D 253
VAL D 297
1.74A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.02A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE D 259
LEU D 205
VAL D 204
1.47A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE D 259
LEU D 205
VAL D 202
1.33A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE D  43
LEU D  89
VAL D  35
1.21A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.75A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE C  78
LEU C  75
VAL C  73
1.00A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.23A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE D  78
LEU D  75
VAL D  73
1.15A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 4
ILE C 259
TYR C 209
LEU C 253
VAL C 297
1.76A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.08A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.74A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.33A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ILE A 779
LEU A 786
VAL A 792
1.34A1.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.14A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
(SARS-CoV-2)		3 / 3
THR A 462
VAL A 792
VAL A 166
1.77A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
SER A 692
TYR A 689
ILE A 589
THR A 604
ILE A 579
1.66A13.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.77A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.67A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m71 NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  14
VAL C  16
1.52A10.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
TYR A 521
ASP A 523
SER A 518
TYR A 515
ILE A 562
1.79A13.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.76A13.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.30A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.77A13.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m71 NSP12
NSP8
(SARS-CoV-2)		3 / 3
ILE B 106
LEU B 122
VAL A 398
1.50A3.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
(SARS-CoV-2)		3 / 3
THR A 462
VAL A 792
VAL A 166
1.77A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.78A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
NSP8
(SARS-CoV-2)		3 / 3
THR B 123
VAL B 115
VAL A 330
1.74A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ILE A 696
LEU A 749
VAL A 776
1.44A1.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.76A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 521
ASP A 523
SER A 518
TYR A 515
ILE A 562
1.77A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.70A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6m71 NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  13
VAL C  16
1.32A10.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.76A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.11A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.77A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.76A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.28A13.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
(SARS-CoV-2)		3 / 3
THR A 225
VAL A 231
VAL A 233
1.24A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 10
VAL A 342
TYR A 374
ASP A 377
SER A 343
ILE B 120
1.73A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6m71 NSP12
NSP8
(SARS-CoV-2)		3 / 3
THR B 123
VAL B 115
VAL A 330
1.73A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
THR A 624
VAL A 606
VAL A 307
1.24A1.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
ILE A 724
TYR A 723
LEU A 986
VAL A 990
1.50A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE B 702
VAL B1047
TYR B1049
ILE B 891
THR B 863
1.36A11.68
0.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ILE A 345
LEU A 499
VAL A 420
0.95A1.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		3 / 3
THR H 205
VAL H 198
VAL H 196
1.23A5.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6nur NSP12
(SARSr-CoV)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.10A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6nur NSP12
(SARSr-CoV)		5 / 12
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.40A14.04
1.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6nur NSP12
(SARSr-CoV)		5 / 10
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.41A14.04
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6nus NSP12
(SARSr-CoV)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.67A14.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6nus NSP12
(SARSr-CoV)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.68A14.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 4
ILE B 742
TYR B 741
LEU B1004
VAL B1008
1.58A1.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
THR B 323
VAL B 320
VAL B 620
1.15A7.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ILE A 358
LEU A 513
VAL A 433
1.00A1.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 720
VAL B1065
TYR B1067
ILE B 909
THR B 881
1.30A12.40
0.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6vw1 ACE2
(Homo
sapiens)		4 / 4
ILE A 513
TYR A 516
LEU A 450
VAL A 447
1.58A1.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6vw1 ACE2
(Homo
sapiens)		5 / 10
TYR B 199
VAL B 184
TYR B 183
TRP B 459
ILE B 468
1.53A19.20
3.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6vw1 ACE2
(Homo
sapiens)		5 / 12
TYR B 199
VAL B 184
TYR B 183
TRP B 459
ILE B 468
1.56A19.20
4.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE A 720
VAL A1065
TYR A1067
ILE A 909
THR A 881
1.25A11.96
0.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
THR A 376
VAL A 510
VAL A 401
0.73A7.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR C  91
SER C  94
TYR C 265
ILE C 101
TRP C 104
1.57A12.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR C  91
SER C  94
TYR C 265
ILE C 101
TRP C 104
1.56A12.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR B  91
SER B  94
TYR B 265
ILE B 101
TRP B 104
1.55A11.96
1.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR B  91
SER B  94
TYR B 265
ILE B 101
TRP B 104
1.48A12.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
THR A 376
VAL A 510
VAL A 401
0.72A7.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE C 720
VAL C1065
TYR C1067
ILE C 909
THR C 881
1.28A11.96
0.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		3 / 3
ILE C 358
LEU C 513
VAL C 433
0.90A6.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
ILE L 117
LEU H 124
VAL H 211
1.71A5.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
THR H 116
VAL H  11
VAL H 109
1.69A8.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
THR H 116
VAL H  11
VAL H 109
1.74A8.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
ILE L  48
LEU L  33
VAL L  27
1.53A5.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
THR H 165
VAL H 198
VAL H 207
1.39A8.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
THR H 165
VAL H 198
VAL H 207
1.36A8.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 4
ILE L  21
TYR L  86
LEU L  47
VAL L  58
1.58A5.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6w4h NSP16
(SARS-CoV-2)		5 / 12
ILE A6967
TYR A6930
SER A6927
THR A6934
ILE A6951
1.53A20.99
5.52
None
ACT  A7103 (-4.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A7005
LEU A6924
VAL A6859
1.72A8.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A6866
LEU A6924
VAL A6859
1.67A8.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A7065
LEU A7078
VAL A7057
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE A6967
TYR A6930
SER A6927
THR A6934
ILE A6951
1.43A20.65
8.25
None
KCX  A6935 ( 4.7A)
None
KCX  A6935 ( 3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A7005
LEU A6857
VAL A6859
1.56A8.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.02A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.73A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  95
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ILE B  69
LEU B  75
VAL B  95
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ILE A6967
TYR A6930
SER A6927
THR A6934
ILE A6951
1.38A19.51
6.93
None
FMT  A7103 ( 4.4A)
None
FMT  A7103 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE C7005
LEU C6924
VAL C6859
1.69A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE A7065
LEU A7078
VAL A7057
1.37A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE A7005
LEU A6924
VAL A6859
1.71A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE C7005
LEU C6857
VAL C6859
1.53A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE A6866
LEU A6924
VAL A6859
1.65A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP10
(SARS-CoV-2)		4 / 4
ILE D4334
TYR D4329
LEU D4328
VAL D4361
1.55A6.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE C6866
LEU C6924
VAL C6859
1.65A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE C7065
LEU C7078
VAL C7057
1.44A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR C6950
ILE C6951
SER C6927
ILE C6926
THR C6918
1.68A19.51
6.93
None
None
None
None
FMT  C7113 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w75 NSP16
(SARS-CoV-2)		3 / 3
ILE A7005
LEU A6857
VAL A6859
1.53A7.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
THR C  42
VAL C  57
VAL C  11
1.78A4.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
THR C  42
VAL C  57
VAL C  11
1.77A4.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
THR A  42
VAL A  57
VAL A  11
1.72A4.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A 222
LEU A 185
VAL A 235
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
THR A  42
VAL A  57
VAL A  11
1.73A4.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
THR B  42
VAL B  57
VAL B  11
1.77A4.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
THR B  42
VAL B  57
VAL B  11
1.77A4.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
ILE C 222
LEU C 185
VAL C 235
0.97A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wcf NSP3
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  95
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wen NSP3
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  95
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wey NSP3
(SARS-CoV-2)		3 / 3
ILE A 273
LEU A 279
VAL A 299
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wiq NSP7
(SARS-CoV-2)		3 / 3
ILE A  39
LEU A  13
VAL A  16
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wiq NSP7
(SARS-CoV-2)		3 / 3
ILE A  68
LEU A  59
VAL A  58
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wiq NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.63A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wiq NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.65A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wiq NSP8
(SARS-CoV-2)		5 / 12
ILE B 172
VAL B 167
ASP B 161
ILE B 185
ILE B 132
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR C6950
ILE C6951
SER C6927
ILE C6926
THR C6918
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A7065
LEU A7078
VAL A7057
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE A6967
TYR A6930
SER A6927
THR A6934
ILE A6951
1.38A
None
FMT  A7103 ( 4.3A)
None
FMT  A7103 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE C6967
TYR C6930
SER C6927
THR C6934
ILE C6951
1.42A
None
FMT  C7104 ( 4.2A)
None
FMT  C7104 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE C7065
LEU C7078
VAL C7057
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ILE A6967
TYR A6930
SER A6927
THR A6934
ILE A6951
1.39A
None
FMT  A7105 ( 4.4A)
None
FMT  A7105 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ILE A7005
LEU A6857
VAL A6859
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ILE A7065
LEU A7078
VAL A7057
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wkq NSP16
(SARS-CoV-2)		3 / 3
ILE C7065
LEU C7078
VAL C7057
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ILE C6967
TYR C6930
SER C6927
THR C6934
ILE C6951
1.47A
None
FMT  C7104 ( 4.3A)
None
FMT  C7104 ( 4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR C6950
ILE C6951
SER C6927
ILE C6926
THR C6918
1.72A
None
None
None
None
FMT  C7108 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR A 275
VAL A 321
VAL A 319
1.66A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR B 326
VAL B 276
VAL B 295
1.74A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR A 326
VAL A 276
VAL A 295
1.79A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR A  99
VAL A  54
VAL A  52
1.68A5.13
None
EDO  A 403 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ILE A 100
LEU A 134
VAL A 132
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR B  99
VAL B  54
VAL B  52
1.67A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ILE B 307
LEU B 332
VAL B 314
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR A 326
VAL A 276
VAL A 295
1.76A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR A 275
VAL A 321
VAL A 319
1.65A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR B  99
VAL B  54
VAL B  52
1.69A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ILE B 100
LEU B 134
VAL B 132
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ILE A 328
LEU A 346
VAL A 292
1.54A
None
U5P  A 401 (-4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR B 275
VAL B 321
VAL B 319
1.72A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR A  99
VAL A  54
VAL A  52
1.66A5.13
None
EDO  A 403 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR B 275
VAL B 321
VAL B 319
1.71A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
THR B 326
VAL B 276
VAL B 295
1.77A5.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ILE A 116
LEU B 120
VAL B 122
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.71A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.01A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE C  69
LEU C  75
VAL C  95
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE C  69
LEU C  75
VAL C  77
1.13A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE D  69
LEU D  75
VAL D  77
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE D  69
LEU D  75
VAL D  95
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  95
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE B  69
LEU B  75
VAL B  95
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A7005
LEU A6857
VAL A6859
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ILE A6967
TYR A6930
SER A6927
THR A6934
ILE A6951
1.46A
None
GTA  A7102 ( 3.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ILE A7065
LEU A7078
VAL A7057
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
THR D  93
VAL C  12
VAL A  12
1.79A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
THR B  93
VAL A  12
VAL C  12
1.79A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.66A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
THR B  93
VAL A  12
VAL C  12
1.79A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP8
(SARS-CoV-2)		3 / 3
THR D 141
VAL D 186
VAL D 160
1.64A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wqd NSP7
(SARS-CoV-2)		3 / 3
ILE A  39
LEU A  13
VAL A  16
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.63A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wqd NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  13
VAL C  16
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP7
NSP8
(SARS-CoV-2)		3 / 3
THR D  93
VAL C  12
VAL A  12
1.79A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqd NSP8
(SARS-CoV-2)		3 / 3
THR D 141
VAL D 186
VAL D 160
1.67A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
THR A  26
VAL A  68
VAL A  77
1.45A3.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.73A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
THR A  26
VAL A  68
VAL A  77
1.43A3.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wrh PEPTIDASE C16
(SARS-CoV-2)		3 / 3
THR A  42
VAL A  57
VAL A  11
1.77A4.94
None
None
CL  A 506 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6wrh PEPTIDASE C16
(SARS-CoV-2)		3 / 3
THR A  42
VAL A  57
VAL A  11
1.77A4.94
None
None
CL  A 506 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6wrh PEPTIDASE C16
(SARS-CoV-2)		3 / 3
ILE A 222
LEU A 185
VAL A 235
0.98A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6xdc PROTEIN 3A
(SARS-CoV-2)		5 / 12
TYR A 184
TYR A 156
TYR A 160
THR A 151
ILE A 167
1.43A20.83
5.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		6xdc PROTEIN 3A
(SARS-CoV-2)		5 / 12
TYR B 184
TYR B 156
TYR B 160
THR B 151
ILE B 167
1.44A20.83
5.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.73A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 208
VAL A 204
1.59A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  18
1.61A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.35A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
0.99A12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D 137
VAL D 186
VAL D 160
1.79A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D 141
VAL D 186
VAL D 160
1.65A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D 141
VAL D 186
VAL D 160
1.68A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B  93
VAL A  12
VAL C  12
1.77A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D 145
VAL D 186
VAL D 130
1.39A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D 137
VAL D 186
VAL D 160
1.78A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B 145
VAL B 186
VAL B 130
1.38A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B  93
VAL A  12
VAL C  12
1.77A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D  93
VAL C  12
VAL A  12
1.75A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.67A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B 145
VAL B 186
VAL B 130
1.40A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ILE A  39
LEU A  13
VAL A  16
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ILE B 106
LEU B  95
VAL A   6
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  13
VAL C  16
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B 137
VAL B 186
VAL B 160
1.79A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B 137
VAL B 186
VAL B 160
1.78A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D 145
VAL D 186
VAL D 130
1.41A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR D  93
VAL C  12
VAL A  12
1.75A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.65A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
ILE B 119
LEU A  17
VAL A  16
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 4
ILE L  21
TYR L  92
LEU L  53
VAL L  64
1.59A3.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yla HEAVY CHAIN
(Homo
sapiens)		3 / 3
THR B 120
VAL B  11
VAL B 115
1.24A9.20
None
DMS  H 303 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 4
ILE C  21
TYR C  92
LEU C  53
VAL C  64
1.59A3.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yla HEAVY CHAIN
(Homo
sapiens)		3 / 3
THR B 120
VAL B  11
VAL B 115
1.23A9.20
None
DMS  H 303 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ILE E 358
LEU E 513
VAL E 433
0.97A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6ym0 HEAVY CHAIN
(Homo
sapiens)		3 / 3
THR H 169
VAL H 202
VAL H 211
1.35A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6ym0 HEAVY CHAIN
(Homo
sapiens)		3 / 3
THR H 169
VAL H 202
VAL H 211
1.33A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.69A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.16A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 4
ILE L  21
TYR L  92
LEU L  53
VAL L  64
1.59A3.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 4
ILE C  21
TYR C  92
LEU C  53
VAL C  64
1.60A3.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yor IGG H CHAIN
(Homo
sapiens)		3 / 3
THR H 120
VAL H  11
VAL H 115
1.17A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yor IGG H CHAIN
(Homo
sapiens)		3 / 3
THR B 120
VAL B  11
VAL B 115
1.25A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yor IGG H CHAIN
(Homo
sapiens)		3 / 3
THR H 120
VAL H  11
VAL H 115
1.17A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		6yor IGG H CHAIN
(Homo
sapiens)		3 / 3
THR B 120
VAL B  11
VAL B 115
1.23A9.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.71A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.09A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE C  69
LEU C  75
VAL C  95
1.29A
None
EPE  C 202 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE E  69
LEU E  75
VAL E  95
1.29A
None
EPE  E 203 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE B  69
LEU B  75
VAL B  95
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  95
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE C  69
LEU C  75
VAL C  77
1.13A
None
EPE  C 202 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE E  69
LEU E  75
VAL E  95
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE C  69
LEU C  75
VAL C  95
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE C  69
LEU C  75
VAL C  95
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE C  23
LEU C 153
VAL C  16
1.34A
EDO  C 206 (-4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  77
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE A  69
LEU A  75
VAL A  95
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ILE B  69
LEU B  75
VAL B  95
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.02A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.25A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.72A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7btf NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  14
VAL C  16
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 12
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.24A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.73A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.74A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.73A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
NSP8
(SARS-CoV-2)		3 / 3
THR A 393
VAL B 131
VAL B 186
1.59A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 10
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.72A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.06A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
(SARS-CoV-2)		3 / 3
THR A 801
VAL A 764
VAL A 605
1.59A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.08A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.75A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 12
SER A 692
TYR A 689
ILE A 589
THR A 604
ILE A 579
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 12
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7btf NSP12
(SARS-CoV-2)		3 / 3
ILE A 696
LEU A 749
VAL A 776
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.75A13.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7btf NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  13
VAL C  16
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
NSP8
(SARS-CoV-2)		3 / 3
THR A 393
VAL B 131
VAL B 186
1.58A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.25A13.73
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
(SARS-CoV-2)		3 / 3
THR A 801
VAL A 764
VAL A 605
1.62A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.64A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7btf NSP12
(SARS-CoV-2)		3 / 3
THR A 556
VAL A 667
VAL A 675
1.30A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ILE A 259
LEU A 205
VAL A 204
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  78
LEU A  75
VAL A  73
1.01A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ILE A  43
LEU A  89
VAL A  35
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 4
ILE A 259
TYR A 209
LEU A 253
VAL A 297
1.76A4.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 225
VAL A 231
VAL A 233
1.10A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.70A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 686
VAL A 693
VAL A 476
1.72A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.08A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bv1 NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  13
VAL C  16
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 225
VAL A 231
VAL A 233
1.13A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.71A13.71
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 556
VAL A 667
VAL A 675
1.31A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 801
VAL A 764
VAL A 605
1.59A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.78A13.71
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 556
VAL A 667
VAL A 675
1.34A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ILE A 696
LEU A 749
VAL A 776
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP8
(SARS-CoV-2)		3 / 3
THR D 145
VAL D 186
VAL D 130
1.40A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ILE A 779
LEU A 786
VAL A 792
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.69A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
NSP8
(SARS-CoV-2)		3 / 3
THR A 393
VAL B 131
VAL B 186
1.62A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.30A13.71
1.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 801
VAL A 764
VAL A 605
1.57A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP8
(SARS-CoV-2)		3 / 3
THR D 145
VAL D 186
VAL D 130
1.42A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.06A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
NSP8
(SARS-CoV-2)		3 / 3
THR A 393
VAL B 131
VAL B 186
1.63A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.70A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.71A13.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
SER A 692
TYR A 689
ILE A 589
THR A 604
ILE A 579
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.70A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.73A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
THR A 686
VAL A 693
VAL A 476
1.76A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bv1 NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  14
VAL C  16
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.03A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.66A
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bv2 NSP7
(SARS-CoV-2)		3 / 3
ILE C  39
LEU C  13
VAL C  16
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.26A13.71
1.14
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
THR A 462
VAL A 792
VAL A 166
1.80A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP8
(SARS-CoV-2)		3 / 3
THR B 145
VAL B 186
VAL B 160
1.54A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.75A
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
THR A 801
VAL A 764
VAL A 605
1.61A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
THR A 586
VAL A 476
VAL A 472
1.05A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.74A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP8
(SARS-CoV-2)		3 / 3
THR B 141
VAL B 186
VAL B 160
1.72A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.68A13.71
1.14
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.66A13.82
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.67A13.82
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRI_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
VAL A 693
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.74A13.71
1.14
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
PEP-V)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ILE A 779
LEU A 786
VAL A 792
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.66A13.82
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
THR A 801
VAL A 764
VAL A 605
1.58A1.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
TYR A 479
SER A 692
TYR A 689
ILE A 589
ILE A 579
1.25A13.71
1.47
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 483
VAL A 587
TYR A 689
TYR A 479
ILE A 696
1.67A13.82
None
None
U  T  12 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_2
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
VAL-THR-THR-ASP-ILE-
GLN-VAL-LYS-VAL)		7bv2 NSP8
(SARS-CoV-2)		3 / 3
THR B 145
VAL B 186
VAL B 160
1.53A4.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
SER A 692
TYR A 689
ILE A 589
THR A 604
ILE A 579
1.57A
None
U  T  12 ( 4.8A)
None
None
None